Table 2 Study characteristics of studies describing consecutive patients suspected of CVT
Study design | All/isolated headache patients | D-dimer test | Cut-off value | Imaging | Missing information | |
|---|---|---|---|---|---|---|
Tardy et al. [16] | Prospective | 52/23 | ELISA Vidas assay | >0.5 μg/ml | MRA | None missing |
Kosinski, et al. [14] | Prospective | 343/291 | 2nd generation latexagglutination | >0.5 μg/ml | MRA or CTV | None missing |
Meng, et al. [17] | Prospective | 233/173 | Immuno- turbidimetric assay | >0.5 | MRI/MRV | None missing |
Tanislav et al. [23] | Retrospective | 239/X | Turbidimetric | >0.19 μg/ml | CTV or MRV | Isolated headache unclear |
Ghaffarpour et al. [24] | Prospective | 104/X | Conventional ELISA | >0.5 μg/ml | Isolated headache unclear | |
Gouda, Sabry [21] | Prospective | 104/X | 2nd generation latexagglutination | >0.5 μg/ml | TOF MRA | isolated headache unclear in non CVT group |
Lalive, et al. [20] | Prospective | 54/X | ELISA Vidas assay | >0.5 μg/ml | MRA | Isolated headache unclear in non CVT group |
Cucchiara, et al. [22] | Prospective | 31/X | ELISA Vidas assay | >0.5 μg/ml | MRV | Isolated headache unclear in non CVT group |